Portal de Periódicos da CAPES

Cyclosporine consensus conference: With emphasis on the treatment of psoriasis

1998; Elsevier BV; Volume: 39; Issue: 3 Linguagem: Inglês

10.1016/s0190-9622(98)70325-1

1097-6787

Mark Lebwohl, Charles N. Ellis, Alice B. Gottlieb, John Koo, Gerald G. Krueger, Kenneth G. Linden, Jerome L. Shupack, Gerald Weinstein,

Hematopoietic Stem Cell Transplantation

Abstract Cyclosporine has been in worldwide use for 15 years for patients who have undergone transplantation operations and is now being used to control inflammatory reactions in other organs (eg, joints, bowel, and skin). Neoral, a more consistently absorbed form of cyclosporine, has recently been approved by the Food and Drug Administration for the treatment of psoriasis. This report outlines the indications, contraindications, dosage recommendations, monitoring requirements, adverse events, drug interactions, interactions with other psoriasis treatments, and suggestions for cyclosporine's use in rotational therapy. (J Am Acad Dermatol 1998;39:464-75.)